Rothschild & Co Redburn upgraded shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports.
Novozymes A/S Stock Performance
Shares of NVZMY stock opened at $58.98 on Friday. The stock has a 50-day moving average of $59.32 and a 200-day moving average of $61.44. The stock has a market cap of $24.45 billion, a PE ratio of 42.13, a price-to-earnings-growth ratio of 1.05 and a beta of 1.11. Novozymes A/S has a one year low of $49.90 and a one year high of $75.99. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.72 and a quick ratio of 1.00.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.44). Novozymes A/S had a net margin of 13.96% and a return on equity of 6.37%. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.22 billion. As a group, sell-side analysts expect that Novozymes A/S will post 1.82 earnings per share for the current year.
About Novozymes A/S
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
Further Reading
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
